Status:
NOT_YET_RECRUITING
Maintenance Electroconvulsive Therapy (ECT) Versus Aripiprazole in Clozapine-resistant Schizophrenia
Lead Sponsor:
All India Institute of Medical Sciences, Bhubaneswar
Conditions:
Clozapine Resistant Schizophrenia
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
The pharmacological treatment options in schizophrenia developing resistance to clozapine are limited. Few studies have found ECT as beneficial in TRS, including CRS. However, literature on the role o...
Eligibility Criteria
Inclusion
- Patients clinically diagnosed with CRS (currently under clozapine)
- Patients aged 18-60 years of either sex.
- LAR giving voluntary written consent for participation in the study
Exclusion
- Patient already on ECT or aripiprazole.
- History of psychoactive substance abuse or dependence.
- Co-morbid psychiatric, major medical or neurological disorders.
- History of organicity or significant head injury.
- Pacemaker or metal in any body part, excluding the mouth. Pregnant and breastfeeding females.
Key Trial Info
Start Date :
August 10 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2026
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06501339
Start Date
August 10 2024
End Date
March 31 2026
Last Update
July 16 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.